Company intelligence / Profile preview

Prismic Pharmaceuticals

Scottsdale, Arizona, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Prismic’s lead candidate, PP-101 (micro-PEA 600 mg tablet), was anticipated to enter Phase 2/3 trials (as of 2019) for fibromyalgia as an adjunct with pregabalin. The company’s drug candidates combine micro-PEA with established pain medications and have reached at least Phase 1 development. Their main clinical focus is on non-opioid, non-addictive prescription drugs for pain and neurological indications[1][3].

Therapeutic areas: ImmunologyNeurologyRheumatologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

Epitech Group SRL

Beyond the preview

Go deeper on Prismic Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prismic Pharmaceuticals.

Explore the full profile